Skip to main content
Top
Published in: Diabetologia 11/2019

Open Access 01-11-2019 | Type 2 Diabetes | Article

In search of causal pathways in diabetes: a study using proteomics and genotyping data from a cross-sectional study

Authors: Kristina Beijer, Christoph Nowak, Johan Sundström, Johan Ärnlöv, Tove Fall, Lars Lind

Published in: Diabetologia | Issue 11/2019

Login to get access

Abstract

Aims/hypothesis

The pathogenesis of type 2 diabetes is not fully understood. We investigated whether circulating levels of preselected proteins were associated with the outcome ‘diabetes’ and whether these associations were causal.

Methods

In 2467 individuals of the population-based, cross-sectional EpiHealth study (45–75 years, 50% women), 249 plasma proteins were analysed by the proximity extension assay technique. DNA was genotyped using the Illumina HumanCoreExome-12 v1.0 BeadChip. Diabetes was defined as taking glucose-lowering treatment or having a fasting plasma glucose of ≥7.0 mmol/l. The associations between proteins and diabetes were assessed using logistic regression. To investigate causal relationships between proteins and diabetes, a bidirectional two-sample Mendelian randomisation was performed based on large, genome-wide association studies belonging to the DIAGRAM and MAGIC consortia, and a genome-wide association study in the EpiHealth study.

Results

Twenty-six proteins were positively associated with diabetes, including cathepsin D, retinal dehydrogenase 1, α-l-iduronidase, hydroxyacid oxidase 1 and galectin-4 (top five findings). Three proteins, lipoprotein lipase, IGF-binding protein 2 and paraoxonase 3 (PON-3), were inversely associated with diabetes. Fourteen of the proteins are novel discoveries. The Mendelian randomisation study did not disclose any significant causal effects between the proteins and diabetes in either direction that were consistent with the relationships found between the protein levels and diabetes.

Conclusions/interpretation

The 29 proteins associated with diabetes are involved in several physiological pathways, but given the power of the study no causal link was identified for those proteins tested in Mendelian randomisation. Therefore, the identified proteins are likely to be biomarkers for type 2 diabetes, rather than representing causal pathways.
Appendix
Available only for authorised users
Literature
1.
10.
go back to reference Meng Q, Ge S, Yan W et al (2017) Screening for potential serum-based proteomic biomarkers for human type 2 diabetes mellitus using MALDI-TOF MS. Proteomics Clin Appl 11:3–4CrossRef Meng Q, Ge S, Yan W et al (2017) Screening for potential serum-based proteomic biomarkers for human type 2 diabetes mellitus using MALDI-TOF MS. Proteomics Clin Appl 11:3–4CrossRef
37.
go back to reference Chung CM, Lin TH, Chen JW et al (2014) Common quantitative trait locus downstream of RETN gene identified by genome-wide association study is associated with risk of type 2 diabetes mellitus in Han Chinese: a Mendelian randomization effect. Diabetes Metab Res Rev 30(3):232–240. https://doi.org/10.1002/dmrr.2481 CrossRefPubMed Chung CM, Lin TH, Chen JW et al (2014) Common quantitative trait locus downstream of RETN gene identified by genome-wide association study is associated with risk of type 2 diabetes mellitus in Han Chinese: a Mendelian randomization effect. Diabetes Metab Res Rev 30(3):232–240. https://​doi.​org/​10.​1002/​dmrr.​2481 CrossRefPubMed
Metadata
Title
In search of causal pathways in diabetes: a study using proteomics and genotyping data from a cross-sectional study
Authors
Kristina Beijer
Christoph Nowak
Johan Sundström
Johan Ärnlöv
Tove Fall
Lars Lind
Publication date
01-11-2019
Publisher
Springer Berlin Heidelberg
Keyword
Type 2 Diabetes
Published in
Diabetologia / Issue 11/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-4960-8

Other articles of this Issue 11/2019

Diabetologia 11/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.